Quoin Pharmaceuticals Ltd. (the " Company ") Convening of a Special General Meeting of the Company The Company hereby gives notice of a Special General Meeting (the " Meeting ") that will take place on Monday, the 28th o

Quoin Pharmaceuticals Ltd. (the "Company")

Convening of a Special General Meeting of the Company

The Company hereby gives notice of a Special General Meeting (the "Meeting")

that will take place on Monday, the 28th of February, 2022, at 4 p.m., at the offices of the Company's Israeli counsel S. Horowitz &

Co., at 31 Ahad Ha-Am St., Tel Aviv. If a quorum is not present, the Meeting will be adjourned by one week, to Monday, the 7th

of March, 2022, at the same time and place.

Approval of a proposed amendment and restatement of the Company's Articles

The record date for determining a shareholder's eligibility to

vote at the Meeting is Wednesday, the 2nd of February, 2022 ("Record Date").

Shareholders may vote regarding the aforementioned resolution by attending

the Meeting in person or by proxy. If you are a shareholder of record on the Record Date and do not return your proxy card, your ordinary

shares will not be voted. If you hold ordinary shares (or ordinary shares represented by American Depository Shares ("ADS"))

beneficially in street name, your shares will also not be voted at the Meeting if you do not return your voting instruction form instructing

your broker or The Bank of New York Mellon ("BNY Mellon") how to vote. Brokers and BNY Mellon may only vote in accordance

with instructions from a beneficial owner of ordinary shares or ADSs. A proxy card and voting instruction form will be made available

on the website of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov. Proxy cards should be delivered

to the Company c/o the offices of the Company's Israeli counsel as listed above, no later than 48 hours before the scheduled time of the

Meeting. Holders of ADS shares must cast their vote according to the procedure and deadline provided by BNY Mellon.

In connection with the Meeting, the Company will furnish a proxy statement

and other relevant documents to the SEC, as exhibits to Form 6-K. SHAREHOLDERS ARE ADVISED TO READ THE PROXY STATEMENT WHEN IT BECOMES

AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FURNISHED TO THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS (IF ANY),

BECAUSE THEY WILL CONTAIN THE FULL TEXT OF THE NEW ARTICLES AND OTHER IMPORTANT INFORMATION. Shareholders may obtain a free copy of

the proxy statement (when available) and other documents furnished by the Company to the SEC at the SEC's website at http://www.sec.gov.

Quoin Pharmaceuticals Ltd.